Eton Pharmaceuticals Inc.

26 days ago · globenewswire.com

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.

1 month ago · fool.com

Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.

1 month ago · seekingalpha.com

Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.

1 month ago · seekingalpha.com

Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

1 month ago · marketbeat.com

Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.

1 month ago · zacks.com

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.

1 month ago · globenewswire.com

DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2026.

2 months ago · globenewswire.com

DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

2 months ago · globenewswire.com

DEER PARK, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company's new formulation of KHINDIVI (hydrocortisone) oral solution successfully showed bioequivalence to ALKINDI SPRINKLE (hydrocortisone) oral granules, the FDA-approved hydrocortisone granule formulation, and the Company has submitted a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) requesting an expansion of the product's label to include younger pediatric patients. KHINDIVI is currently approved for patients ages five years and above.

2 months ago · zacks.com

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.